Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation

J Thorac Oncol. 2018 Aug;13(8):e145-e147. doi: 10.1016/j.jtho.2018.03.017.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / enzymology
  • Adenocarcinoma of Lung / genetics
  • Adenocarcinoma of Lung / pathology
  • Adult
  • Aminopyridines
  • Anaplastic Lymphoma Kinase / genetics*
  • Female
  • Humans
  • Lactams
  • Lactams, Macrocyclic / therapeutic use*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / enzymology*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Mutation
  • Point Mutation
  • Pyrazoles

Substances

  • Aminopyridines
  • Lactams
  • Lactams, Macrocyclic
  • Pyrazoles
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • lorlatinib